Cargando…
Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab
Sarcopenia is a muscle loss syndrome known as a risk factor of various carcinomas. The impact of sarcopenia and sarcopenia-related inflammatory/nutritional markers in metastatic urothelial carcinoma (mUC) treated with pembrolizumab was unknown, so this retrospective study of 27 patients was performe...
Autores principales: | Shimizu, Takuto, Miyake, Makito, Hori, Shunta, Ichikawa, Kazuki, Omori, Chihiro, Iemura, Yusuke, Owari, Takuya, Itami, Yoshitaka, Nakai, Yasushi, Anai, Satoshi, Tomioka, Atsushi, Tanaka, Nobumichi, Fujimoto, Kiyohide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277993/ https://www.ncbi.nlm.nih.gov/pubmed/32429323 http://dx.doi.org/10.3390/diagnostics10050310 |
Ejemplares similares
-
Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study
por: Shimizu, Takuto, et al.
Publicado: (2022) -
Emerging biomarkers for the diagnosis and monitoring of urothelial carcinoma
por: Miyake, Makito, et al.
Publicado: (2018) -
Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
por: Nishimura, Nobutaka, et al.
Publicado: (2022) -
Inhibitory Effect of Orally Administered 5-Aminolevulinic Acid on Prostate Carcinogenesis in the FVB-Transgenic Adenocarcinoma of a Mouse Prostate (FVB-TRAMP) Model
por: Onishi, Kenta, et al.
Publicado: (2020) -
The diagnostic utility of retroperitoneoscopic tissue biopsy for unresectable retroperitoneal lesions excluding urogenital cancers
por: Miyake, Makito, et al.
Publicado: (2019)